Please assess the completion status of the following clinical trial:

Trial Title: Arachidonic Acid Treatment Against Schistosomiasis Infection in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* consent from parent or legal guardian~* clinically confirmed schistosomiasis~Exclusion Criteria:~* not infected with schistosomiasis~* less than 6 or greater than 15 years of age

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Praziquantel (PZQ) (Type: ACTIVE_COMPARATOR): A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school.
- Arachidonic acid (ARA) (Type: EXPERIMENTAL): A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school.
- PZQ + ARA (Type: EXPERIMENTAL): A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school.

Based on this trial design, predict the completion outcome and termination type (if applicable).